You are here
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
The Independent Hospital Pricing Authority (IHPA) has developed the Australian Mental Health Care Classification Pricing Feasibility Report 2020–21 to provide an overview of the process undertaken by IHPA to shadow price admitted mental health services using the Australian Mental Health Care Classification (AMHCC) Version 1.0.